Tg Therapeutics's 15min Chart Experiences Death Cross, Bearish Marubozu Formation

Based on the technical analysis of Tg Therapeutics' 15-minute chart, the KDJ Death Cross and Bearish Marubozu indicators have been triggered, as of September 12, 2025, at 15:45. This suggests that the momentum of the stock price is shifting towards a downward trend, and there is a potential for further decreases. Sellers are currently in control of the market, and it is likely that this bearish momentum will continue.

TG Therapeutics, Inc. recently announced the commencement of a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody, in people with relapsing forms of multiple sclerosis (RMS). The trial, which started enrolling patients on September 12, 2025, aims to assess the efficacy and safety of BRIUMVI in this patient population TG Therapeutics, Inc. Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment^[1].

In addition to the ongoing Phase 3 trial, TG Therapeutics has received regulatory approvals for BRIUMVI from several agencies, including the U.S. Food and Drug Administration (FDA), the European Commission (EC), the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, Swissmedic in Switzerland, and Australia's Therapeutic Goods Administration (TGA). These approvals cover the treatment of adult patients with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease TG Therapeutics, Inc. Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment^[1].

Technical analysis of TG Therapeutics' stock suggests a potential downward trend. As of September 12, 2025, at 15:45, the KDJ Death Cross and Bearish Marubozu indicators have been triggered. These indicators typically signal a shift in momentum towards a downward trend, suggesting that sellers are currently in control of the market. This bearish momentum may continue, indicating potential further decreases in the stock price .

Investors should closely monitor the outcomes of the Phase 3 trial and the regulatory approval process for BRIUMVI. The success of the trial and the commercialization of the drug could significantly impact TG Therapeutics' financial performance and stock price. However, several risks and uncertainties, such as the ability to maintain market demand, regulatory compliance, and the potential for variations in patient outcomes, could affect the company's projections and estimates TG Therapeutics, Inc. Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment^[1].